Nascent Biotech, Inc. (NBIO)
OTCMKTS · Delayed Price · Currency is USD
0.0003
-0.0003 (-50.00%)
Aug 22, 2025, 4:00 PM EDT
Nascent Biotech Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
51.85K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | 1.00M | 250.00K | 33.33% |
| Mar 31, 2021 | 750.00K | - | - |
| Mar 31, 2020 | - | - | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Glass House Brands | 221.55M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 105.45M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.09M |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
Nascent Biotech News
- 1 year ago - Nascent Biotech Presents at the July Emerging Growth Conference - Accesswire
- 1 year ago - Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run - Accesswire
- 1 year ago - Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System - Accesswire
- 1 year ago - Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates - Accesswire
- 1 year ago - Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued - Accesswire
- 1 year ago - Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk - Accesswire
- 1 year ago - Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier - Accesswire
- 2 years ago - Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer - Accesswire